<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04966234</url>
  </required_header>
  <id_info>
    <org_study_id>cASPerCF_2007_OPBG_2019</org_study_id>
    <secondary_id>2019-004511-31</secondary_id>
    <nct_id>NCT04966234</nct_id>
  </id_info>
  <brief_title>A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection</brief_title>
  <acronym>cASPerCF</acronym>
  <official_title>Prospective Validation and Clinical Evaluation of a New Posaconazole Dosing Regimen for Children and Adolescents With Cystic Fibrosis and Aspergillus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bambino Gesù Hospital and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Exeter</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Consorzio per Valutazioni Biologiche e Farmacologiche</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bambino Gesù Hospital and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will provide: (1) new insights in the prevalence of Aspergillus infection in&#xD;
      children and adolescents with CF aged 8-17 yrs; (2) an in silico modelled dose of&#xD;
      posaconazole for children and adolescents with CF and Aspergillus infection aged 8-17 yrs;&#xD;
      (3) an intensive sampling PK study to define the optimal dose in a limited number of children&#xD;
      and adolescents with CF and Aspergillus infection aged 8-17 yrs; (4) a prospective clinical&#xD;
      validation to reduce the residual variability and to allow investigation into PK-PD; and (5)&#xD;
      an efficacy evaluation of this dosing regimen to treat Aspergillus infection in children and&#xD;
      adolescents with CF to inform future primary efficacy trials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cystic fibrosis (CF) is the most common inherited life-limiting disease in North European&#xD;
      people affecting 90,000 people worldwide with about 45,000 registered in the Patient Registry&#xD;
      of the European Cystic Fibrosis Society (ECFS). Progressive lung damage caused by recurrent&#xD;
      infection and persistent inflammation is the major determinant of survival with a median age&#xD;
      of death at 29 years. Approximately 60% of CF patients are infected with A. fumigatus, a&#xD;
      ubiquitous environmental fungus,and its presence is associated with accelerated lung function&#xD;
      decline. Half of the patients infected with Aspergillus are &lt;18 years of age. Evidence to&#xD;
      guide clinical management of CF-related Aspergillus disease is lacking. A recent survey&#xD;
      showed considerable variability in clinical practice among CF consultants. Two-thirds would&#xD;
      treat Aspergillus colonization in patients with CF and two-thirds would use an azole&#xD;
      antifungal in addition to steroids in the first line treatment of CF-related allergic&#xD;
      bronchopulmonary aspergillosis (ABPA). The results of this survey underscore the limited&#xD;
      evidence available to guide management of Aspergillus infection in CF.&#xD;
&#xD;
      Posaconazole, being one of the 4 licensed triazole antifungals with good efficacy against&#xD;
      Aspergillus species has been chosen as the study drug as it has a better tolerability&#xD;
      compared to itraconazole, less toxicity and drug-drug interactions compared to voriconazole&#xD;
      and can be administered once daily. Posaconazole is licensed in Europe for the prevention of&#xD;
      invasive aspergillus in adult neutropenic patient populations and as salvage therapy for&#xD;
      invasive aspergillosis. Several studies have reported on the safety and tolerability of the&#xD;
      use of posaconazole in children and adolescents with either haematological malignancies, or&#xD;
      chronic granulomatous disease, or those undergoing haematopoietic stem cell transplantation.&#xD;
      Currently, no dosing algorithm is available to guide posaconazole dosing in children.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-label, randomized, multi-center study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of posaconazole</measure>
    <time_frame>At steady state, day 5-10 of treatment</time_frame>
    <description>The following pharmacokinetic parameter will be calculated using non-compartmental pharmacokinetic analysis: Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of posaconazole</measure>
    <time_frame>At steady state, day 5-10 of treatment</time_frame>
    <description>The following pharmacokinetic parameter will be calculated using non-compartmental pharmacokinetic analysis: Cmin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of posaconazole</measure>
    <time_frame>At steady state, day 5-10 of treatment</time_frame>
    <description>The following pharmacokinetic parameter will be calculated using non-compartmental pharmacokinetic analysis:&#xD;
Tmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of posaconazole</measure>
    <time_frame>At steady state, day 5-10 of treatment</time_frame>
    <description>The following pharmacokinetic parameter will be calculated using non-compartmental pharmacokinetic analysis: Area Under the Curve during 1 dosing interval and over 24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of posaconazole</measure>
    <time_frame>At steady state, day 5-10 of treatment</time_frame>
    <description>The following pharmacokinetic parameter will be calculated using non-compartmental pharmacokinetic analysis: Clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of posaconazole</measure>
    <time_frame>At steady state, day 5-10 of treatment</time_frame>
    <description>The following pharmacokinetic parameter will be calculated using non-compartmental pharmacokinetic analysis: Distribution volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of posaconazole</measure>
    <time_frame>At steady state, day 5-10 of treatment</time_frame>
    <description>The following pharmacokinetic parameter will be calculated using non-compartmental pharmacokinetic analysis: Half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspergillus isolation from sputum cultures</measure>
    <time_frame>3 months after randomisation</time_frame>
    <description>For evaluating the clinical efficacy of posaconazole, the outcome measure that will be analysed is the number of children with negative sputum sample for Aspergillus 3 months after randomisation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of posaconazole</measure>
    <time_frame>Day 21-35 and day 84 of treatment</time_frame>
    <description>The following pharmacokinetic parameters will be calculated using non-compartmental pharmacokinetic analysis: Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of posaconazole</measure>
    <time_frame>Day 21-35 and day 84 of treatment</time_frame>
    <description>The following pharmacokinetic parameters will be calculated using non-compartmental pharmacokinetic analysis: Cmin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of posaconazole</measure>
    <time_frame>Day 21-35 and day 84 of treatment</time_frame>
    <description>The following pharmacokinetic parameters will be calculated using non-compartmental pharmacokinetic analysis: Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of posaconazole</measure>
    <time_frame>Day 21-35 and day 84 of treatment</time_frame>
    <description>The following pharmacokinetic parameters will be calculated using non-compartmental pharmacokinetic analysis: Area Under the Curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of posaconazole</measure>
    <time_frame>Day 21-35 and day 84 of treatment</time_frame>
    <description>The following pharmacokinetic parameters will be calculated using non-compartmental pharmacokinetic analysis: Clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of posaconazole</measure>
    <time_frame>Day 21-35 and day 84 of treatment</time_frame>
    <description>The following pharmacokinetic parameters will be calculated using non-compartmental pharmacokinetic analysis: Distribution volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of posaconazole</measure>
    <time_frame>Day 21-35 and day 84 of treatment</time_frame>
    <description>The following pharmacokinetic parameters will be calculated using non-compartmental pharmacokinetic analysis: Half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with a favourable clinical response and no signs of Aspergillus infection</measure>
    <time_frame>3, 6 and 12 months after randomisation</time_frame>
    <description>Percentage of patients who have a favourable clinical response (defined by pulmonary exacerbation rate, days on antibiotics and corticosteroids, hospital admissions, change in FEV1, change in BMI, CT-chest abnormalities, QoL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with no signs of Aspergillus infection</measure>
    <time_frame>3, 6 and 12 months after randomisation</time_frame>
    <description>Percentage of patients who have no signs of Aspergillus infection (defined by negative sputum cultures and negative serology).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants experiencing AEs and SAEs</measure>
    <time_frame>Up to 1 year after randomisation</time_frame>
    <description>Assessed according to the Division of AIDS (DAIDS), Table for Grading of the NIAID, NIH, and the US Department of Health and Human Services.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Aspergillosis</condition>
  <arm_group>
    <arm_group_label>Posaconazole arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>90 patients (out of the 135 total patients, therefore with a 2:1 randomization ratio) will receive posaconazole for 12 weeks. Patients in the posaconazole arm will be stratified for body weight and positive sputum cultures for Aspergillus species.&#xD;
Patients will be followed-up for a total of 12 months post-randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>45 patients (out of the 135 total patients, therefore with a 2:1 randomization ratio) will not receive the active treatment.&#xD;
Patients will be followed-up for a total of 12 months post-randomization. If participants in the control arm are deteriorating during the first 3 months after randomization, it is up to the treating physician to consider treatment for the initial asymptomatic Aspergillus infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Posaconazole 100 MG [Noxafil]</intervention_name>
    <description>Posaconazole is a lipophilic, highly permeable triazole, which is practically insoluble in water. Posaconazole inhibits the enzyme CYP51a (also known as Erg11p or lanosterol demethylase). This enzyme is required for catalysation of an essential step in biosynthesis of ergosterol in filamentous fungi and yeasts.&#xD;
Posaconazole is favoured over itraconazole and voriconazole with respect to palatability, tolerability and toxicity profile</description>
    <arm_group_label>Posaconazole arm</arm_group_label>
    <other_name>gastro-resistant tablets Noxafil® 100 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Posaconazole 40 MG/ML</intervention_name>
    <description>Posaconazole is a lipophilic, highly permeable triazole, which is practically insoluble in water. Posaconazole inhibits the enzyme CYP51a (also known as Erg11p or lanosterol demethylase). This enzyme is required for catalysation of an essential step in biosynthesis of ergosterol in filamentous fungi and yeasts.&#xD;
Posaconazole is favoured over itraconazole and voriconazole with respect to palatability, tolerability and toxicity profile</description>
    <arm_group_label>Posaconazole arm</arm_group_label>
    <other_name>105 ml Noxafil® 40 mg/ml oral suspension</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with cystic fibrosis (genetic diagnosis and/or abnormal sweat test and&#xD;
             clinical phenotype of lung disease)&#xD;
&#xD;
          2. Age ≥ 8 yrs and &lt; 18 yrs&#xD;
&#xD;
          3. Body weight ≥20 kg&#xD;
&#xD;
          4. Presence of Aspergillus infection as defined for this study&#xD;
&#xD;
          5. Clinically stable condition without a significant change in lung function (FEV1 +/-&#xD;
             10%) or significant worsening of respiratory symptoms over the previous month&#xD;
&#xD;
          6. Able to perform lung function test (FEV1%)&#xD;
&#xD;
          7. Able to produce a sputum sample (spontaneous or induced sputum)&#xD;
&#xD;
          8. Informed Consent given&#xD;
&#xD;
          9. If female and of childbearing age must be using highly effective contraception (and&#xD;
             must agree to continue for 7 days after the last dose of investigational medicinal&#xD;
             product [IMP]&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-CF lung disorder&#xD;
&#xD;
          2. Age &lt; 8 yrs or ≥ 18 yrs&#xD;
&#xD;
          3. Body weight &lt; 20 kg&#xD;
&#xD;
          4. Not able to perform lung function test (FEV1%)&#xD;
&#xD;
          5. Unable to produce a sputum sample (spontaneous or induced sputum)&#xD;
&#xD;
          6. Clinically unstable condition with significant change in lung function or significant&#xD;
             worsening of respiratory symptoms&#xD;
&#xD;
          7. Unable to tolerate oral medication&#xD;
&#xD;
          8. Known hypersensitivity to itraconazole or posaconazole, or it's excipients.&#xD;
&#xD;
          9. On active transplant list or transplant recipient&#xD;
&#xD;
         10. Azole resistant Aspergillus sp. cultured&#xD;
&#xD;
         11. Patients receiving terfenadine, ergot alkaloids, astemizole, cisapride, pimozide,&#xD;
             halofantrine, quinidine, or HMG-CoA reductase inhibitors metabolised through CYP3A4&#xD;
             (eg. simvastatin, lovastatin, and atorvastatin)&#xD;
&#xD;
         12. Patients receiving omalizumab&#xD;
&#xD;
         13. Received systemic mould-active antifungals in the last month&#xD;
&#xD;
         14. Shortened or elongated QT interval&#xD;
&#xD;
         15. Cardiac failure&#xD;
&#xD;
         16. ALT ≥ 200 U/L&#xD;
&#xD;
         17. AST ≥ 225 U/L&#xD;
&#xD;
         18. Alkaline phosphatase ≥ 460 U/L&#xD;
&#xD;
         19. Bilirubin ≥ 50 umol/L&#xD;
&#xD;
         20. eGFR &lt; 20 ml/min/1.73 m2 (calculated with the Schwartz formula)&#xD;
&#xD;
         21. Patients with known glucose-galactose malabsorption problems&#xD;
&#xD;
         22. Pregnancy2 or breastfeeding&#xD;
&#xD;
         23. Females of childbearing age who do not intend to use contraception measures.&#xD;
&#xD;
         24. Informed Consent not given&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adilia Warris, Prof</last_name>
    <role>Study Director</role>
    <affiliation>University of Exeter</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Betty Polikar, PhD Op Coord</last_name>
    <phone>+39-06-68594243</phone>
    <email>betty.polikar@opbg.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adilia Warris, MD,C.Inv.</last_name>
    <phone>+44(0)1392 727593</phone>
    <email>a.warris@exeter.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Motol University Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pavel Dřevínek, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire Dijon Bourgogne</name>
      <address>
        <city>Bourgogne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frédéric Huet, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle Pin, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raphaël Chiron, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Katholisches Klinikum Bochum gGMBH, Klinik für Kinder- und Jugendmedizin der Ruhr-Universität Bochum, St. Josef Hospital</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Folke Brinkmann, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Technische Universität Dresden, Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Kinder- und Jugendmedizin</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jutta Hammermann, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen,Pediatric Pulmonology and Cystic Fibrosis Center</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florian Stehling, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Klinik für Pädiatrische Pneumologie, Allergologie und Neonatologie</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Maria Dittrich, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena, Klinik für Kinder- und Jugendmedizin, Pädiatrische Pneumologie/Allergologie/Mukoviszidose-Zentrum</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Lorenz, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cystic Fibrosis Department, &quot;Agia Sofia&quot; Children's Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ioanna Loukou, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cystic Fibrosis Center, 3rd Paediatric Dept, Aristotle University of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Tsanakas, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Muireann Ní Chróinín, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASST Spedali Civili Paediatric department</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raffaele Badolato, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Giannina Gaslini</name>
      <address>
        <city>Genoa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlo Castellani, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Parma Department of Medicine and Surgery</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susanna Esposito, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Alghisi, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen (UMCG)</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Geread Koppelman, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center (RUMC)</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Merkus, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center (EMC)</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Harm Tiddens, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht (UMCU)</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kors van der Ent, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Universitário Lisboa Norte EPE</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Celeste Barreto, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Materno Infantil Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Javier Torres Borrego, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre,Unidad Multidisciplinar Fibrosis Quística</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>María del Carmen Luna Paredes, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marta Ruiz de Valbuena Maiz, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adelaida Lamas Ferreiro, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Zurich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Moeller, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Birmingham Women's and Children's NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maya Desai, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Nottingham (Queens Medical Centre)</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jayesh Bhatt, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheffield Childrens NHS Foundation Trust</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Noreen West, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS FT</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gary Connett, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals of North Midlands NHS Trust</name>
      <address>
        <city>Stoke-on-Trent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francis Gilchrist, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Armstead J, Morris J, Denning DW. Multi-country estimate of different manifestations of aspergillosis in cystic fibrosis. PLoS One. 2014 Jun 10;9(6):e98502. doi: 10.1371/journal.pone.0098502. eCollection 2014.</citation>
    <PMID>24914809</PMID>
  </reference>
  <reference>
    <citation>Rowbotham NJ, Smith S, Prayle AP, Robinson KA, Smyth AR. Gaps in the evidence for treatment decisions in cystic fibrosis: a systematic review. Thorax. 2019 Mar;74(3):229-236. doi: 10.1136/thoraxjnl-2017-210858. Epub 2018 Oct 9.</citation>
    <PMID>30301819</PMID>
  </reference>
  <reference>
    <citation>Boyle M, Moore JE, Whitehouse JL, Bilton D, Downey DG. The diagnosis and management of respiratory tract fungal infection in cystic fibrosis: A UK survey of current practice. Med Mycol. 2019 Feb 1;57(2):155-160. doi: 10.1093/mmy/myy014.</citation>
    <PMID>29554296</PMID>
  </reference>
  <reference>
    <citation>Welzen ME, Brüggemann RJ, Van Den Berg JM, Voogt HW, Gilissen JH, Pajkrt D, Klein N, Burger DM, Warris A. A twice daily posaconazole dosing algorithm for children with chronic granulomatous disease. Pediatr Infect Dis J. 2011 Sep;30(9):794-7. doi: 10.1097/INF.0b013e3182195808.</citation>
    <PMID>21772229</PMID>
  </reference>
  <reference>
    <citation>Groll AH, Abdel-Azim H, Lehrnbecher T, Steinbach WJ, Paschke A, Mangin E, Winchell GA, Waskin H, Bruno CJ. Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial. Int J Antimicrob Agents. 2020 Sep;56(3):106084. doi: 10.1016/j.ijantimicag.2020.106084. Epub 2020 Jul 17.</citation>
    <PMID>32682946</PMID>
  </reference>
  <reference>
    <citation>King J, Brunel SF, Warris A. Aspergillus infections in cystic fibrosis. J Infect. 2016 Jul 5;72 Suppl:S50-5. doi: 10.1016/j.jinf.2016.04.022. Epub 2016 May 11. Review.</citation>
    <PMID>27177733</PMID>
  </reference>
  <reference>
    <citation>Periselneris J, Nwankwo L, Schelenz S, Shah A, Armstrong-James D. Posaconazole for the treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. J Antimicrob Chemother. 2019 Jun 1;74(6):1701-1703. doi: 10.1093/jac/dkz075.</citation>
    <PMID>30805605</PMID>
  </reference>
  <reference>
    <citation>Dolton MJ, Brüggemann RJ, Burger DM, McLachlan AJ. Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis. Antimicrob Agents Chemother. 2014 Nov;58(11):6879-85. doi: 10.1128/AAC.03777-14. Epub 2014 Sep 8.</citation>
    <PMID>25199779</PMID>
  </reference>
  <reference>
    <citation>Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, Sermet-Gaudelus I, Southern KW, Barben J, Flume PA, Hodková P, Kashirskaya N, Kirszenbaum MN, Madge S, Oxley H, Plant B, Schwarzenberg SJ, Smyth AR, Taccetti G, Wagner TOF, Wolfe SP, Drevinek P. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018 Mar;17(2):153-178. doi: 10.1016/j.jcf.2018.02.006. Epub 2018 Mar 3. Review.</citation>
    <PMID>29506920</PMID>
  </reference>
  <reference>
    <citation>Patel D, Popple S, Claydon A, Modha DE, Gaillard EA. Posaconazole therapy in children with cystic fibrosis and Aspergillus-related lung disease. Med Mycol. 2020 Jan 1;58(1):11-21. doi: 10.1093/mmy/myz015.</citation>
    <PMID>30877757</PMID>
  </reference>
  <reference>
    <citation>Krishna G, Ma L, Martinho M, Preston RA, O'Mara E. A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother. 2012 Nov;67(11):2725-30. doi: 10.1093/jac/dks268. Epub 2012 Jul 24.</citation>
    <PMID>22833639</PMID>
  </reference>
  <reference>
    <citation>Tragiannidis A, Herbrüggen H, Ahlmann M, Vasileiou E, Gastine S, Thorer H, Fröhlich B, Müller C, Groll AH. Plasma exposures following posaconazole delayed-release tablets in immunocompromised children and adolescents. J Antimicrob Chemother. 2019 Dec 1;74(12):3573-3578. doi: 10.1093/jac/dkz359.</citation>
    <PMID>31504563</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2021</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Posaconazole</keyword>
  <keyword>Progressive lung damage</keyword>
  <keyword>Recurrent infection</keyword>
  <keyword>Persistent inflammation</keyword>
  <keyword>Better tolerability</keyword>
  <keyword>Paediatrics</keyword>
  <keyword>Adolescents</keyword>
  <keyword>Therapeutic drug monitoring</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Aspergillosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Aspergillosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Posaconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Starting 6 months after the availability of the CSR and therefore from April 2024</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

